Australia markets closed

Centogene N.V. (CNTG)

NasdaqGM - NasdaqGM Real-time price. Currency in USD
Add to watchlist
1.2000-0.0500 (-4.00%)
At close: 03:59PM EST
1.1500 -0.05 (-4.17%)
After hours: 04:19PM EST

Centogene N.V.

Am Strande 7
Rostock 18055
49 381 80113 500

IndustryDiagnostics & Research
Full-time employees808

Key executives

NameTitlePayExercisedYear born
Dr. Andrin Oswald M.D., Ph.D.Advisor479.46kN/A1972
Ms. Kim StrattonCEO & Member of Management BoardN/AN/A1962
Mr. Jose Miguel Coego RiosChief Financial OfficerN/AN/AN/A
Dr. Patrice P. Denefle Ph.D.Chief Scientific OfficerN/AN/A1960
Dr. Florian Vogel Ph.D.Chief Process OfficerN/AN/A1982
Dr. Peter Bauer M.D.Chief Medical & Genomic OfficerN/AN/A1969
Ms. Bettina GoernerChief Data OfficerN/AN/A1984
Amounts are as of 31 December 2021, and compensation values are for the last fiscal year ending on that date. Pay includes salary, bonuses, etc. Exercised is the value of options exercised during the fiscal year. Currency in USD.


Centogene N.V., together with its subsidiaries, focuses on rare diseases that transforms real-world clinical and genetic, or other data into actionable information for patients, physicians, and pharmaceutical companies worldwide. It operates through three segments: Pharmaceutical, Diagnostics, and COVID-19 testing. The company develops rare disease platform, a data and biological repository, which includes epidemiologic, phenotypic, and heterogenetic data that enhances methods for identifying and monitoring rare hereditary diseases and provide solutions that accelerate the development of orphan drugs. It provides various services, including target discovery, early patient recruitment and identification, epidemiological insights, biomarker discovery, and patient monitoring; and genetic sequencing and diagnostics services to physicians, laboratories, or hospitals directly or through distributors. The company also offers COVID-19 testing solutions, including PCR and antigen testing services. It has collaboration and license agreements with Shire International GmbH, Pfizer Inc., Dr. Bauer Laboratoriums GmbH, Fraport AG, Takeda Pharmaceutical Company Limited, and Twist Bioscience Corporation. Centogene N.V. was founded in 2006 and is headquartered in Rostock, Germany.

Corporate governance

Centogene N.V.’s ISS governance QualityScore as of 1 January 2023 is 5. The pillar scores are Audit: 3; Board: 3; Shareholder rights: 6; Compensation: 7.

Corporate governance scores courtesy of Institutional Shareholder Services (ISS). Scores indicate decile rank relative to index or region. A decile score of 1 indicates lower governance risk, while 10 indicates higher governance risk.